144 results about "Bicyclo Compounds" patented technology

A compound of formula (I):wherein:M is hydrogen or a pharmaceutically acceptable salt-forming cation;Y is OR1 or NR2R3,and R1, R2, R3 and M are as defined herein. Also, methods of treating bacterial infection, pharmaceutical compositions, molecular complexes and processes for preparing compounds.

A liquid crystal composition is provided that satisfies at least one characteristic among the characteristics such as a high maximum temperature of a nematic phase, a low minimum temperature of a nematic phase, a small viscosity, a large optical anisotropy, a large dielectric anisotropy, a large specific resistance, a high stability to ultraviolet light and a high stability to heat, or is properly balanced regarding at least two characteristics. An AM device is provided that has a short response time, a large voltage holding ratio, a large contrast ratio, a long service life and so forth. The liquid crystal composition contains a specific tricyclic compound having a large optical anisotropy as the first component and a specific tetracyclic compound having a large dielectric anisotropy as the second component, and may contain a specific bicyclic compound having a particularly small viscosity as the third component. The liquid crystal composition has a nematic phase. The liquid crystal display device contains the liquid crystal composition.

CRF antagonists comprising as an active ingredient, the compound of formula (I) wherein A ring is 5-6 membered mono-cyclic ring which may be substituted; B ring is 5-7 membered unsaturated mono-heterocyclic ring which may be contained another 1-2 of hetero atom(s) and substituted by another substituents; W1 and W2 is carbon atom or nitrogen atom; Z is NR3, oxygen atom, sulfur which may be oxidized or CR4R5; R1 is alkyl, alkenyl or alkynyl that may be substituted, amino which may be protected, hydroxyl which may be protected, S(O)nR6, COR7, or cyclic group which may be substituted; R2 is unsaturated cyclic group which may be substituted.

New bicyclic compounds, their preparation, and their use as antibacterial agents, either alone or in combination with an antibiotic for the treatment of infections caused by β-lactamase-producing pathogenic bacteria, are described.

The present invention provides, among other things, new bicyclo heterocyclic compounds, compositions comprising these heterocyclic compounds, methods of making the heterocyclic compounds, and methods of using these heterocyclic compounds for treating a variety of conditions and disease states associated with, for example, cellular proliferation, inflammation, glycosidase expression, or the low expression of Perlecan.

This invention provides a compound of the formula (I): wherein R<1 >and R<2 >independently represent a hydrogen atom or the like; X represents a covalent bond or the like: A represents a bicyclic, aromatic, saturated or partially unsaturated heterocyclic or carbocyclic group having from 8 to 12 ring atoms; or the like: B represents a phenyl group or a heteroaryl group having from 5 to 6 ring atoms or the like: These compounds are useful for the treatment of disease conditions caused by overactivation of NMDA NR2B receptor such of pain, or the like in mammalian. This invention also provides a pharmaceutical composition comprising the above compound.

The present disclosure is directed to compounds of formula (I), and pharmaceutically acceptable salts thereof, as mPGES-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful in the treatment of pain and / or inflammation from a variety of diseases or conditions, such as asthma, osteoarthritis, rheumatoid arthritis, acute or chronic pain and neurodegenerative diseases.

Providing a liquid crystal composition satisfying at least one of characteristics such as high maximum temperature of nematic phase, low minimum temperature of the nematic phase, small viscosity, suitable optical anisotropy, large negative dielectric anisotropy, large specific resistance, high stability to ultraviolet light and heat, or having a suitable balance regarding at least two of the characteristics; and an AM device having short response time, large voltage holding ratio, large contrast ratio, long service life and so forth. The liquid crystal composition has a negative dielectric anisotropy and contains a specific two-ring compound having a low minimum temperature as a first component, a specific compound having a large negative dielectric anisotropy as a second component, a specific compound having a low viscosity as a third component, and a specific compound having a large negative dielectric anisotropy as a fourth component. The liquid crystal display device contains the composition.

Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally monocyclic and bicyclic compounds and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.

The subject is to provide a liquid crystal composition that satisfies at least one of characteristics such as a high maximum temperature of a nematic phase, a low minimum temperature of a nematic phase, a small viscosity, a suitable optical anisotropy, a negatively large dielectric anisotropy, a large specific resistance and a high stability to ultraviolet light or heat, or that is suitably balanced regarding at least two of the characteristics. The subject is to provide a AM device that has a short response time, a large voltage holding ratio, a large contrast ratio, a long service life and so forth. The invention provides a liquid crystal composition that has negative dielectric anisotropy, including a specific four-ring compound having a high maximum temperature and a negatively large dielectric anisotropy as a first component, a two-ring compound having a small viscosity as a second component, and optionally including a specific compound having a negatively large dielectric anisotropy as a third component, a specific compound having small viscosity as a fourth component and a specific compound having a negatively large dielectric anisotropy as a fifth component. The invention provides also a liquid crystal display device containing this composition.

Acyl sulfonamide, peri-substituted, fused bicyclic ring compounds useful for the treatment or prophylaxis of a prostaglandin-mediated disease or condition are disclosed. The compounds are of the general formula A representative example is:

A novel compound represented by the following formula (1) or a salt thereof: wherein symbol “A” represents a saturated heterocyclic group, a 5-membered heteroaromatic group having two heteroatoms in the ring, a group represented by the formula A1 (R2, R3, and R4 represent hydrogen atom, hydroxyl group, etc.), etc., B represents a group represented by the formula B1 (R11 represents hydrogen atom, hydroxyl group, etc.), etc., R1 represents an alkyl group, and symbol “n” represents an integer of 2 to 6, which has a parathyroid hormone depressing action and showing low toxicity, and a medicament containing the compound or salt thereof as an active ingredient.

Compounds of formula (I)its tautomeric forms, its stereoisomers, its polymorphs, its pharmaceutically acceptable salts or its pharmaceutically acceptable solvates can be used to prevent or treat diabetes caused by insulin resistance or impaired glucose tolerance or complications of diabetes caused by insulin resistance or impaired glucose tolerance. The compounds can also be used to reduce cholesterol, body weight, blood glucose, triglycerides and free fatty acids in the blood.

Compounds as modulators of peroxisome proliferator activated receptors, pharmaceutical compositions comprising the same, and methods of treating disease using the same are disclosed.

A liquid crystal composition has a negative dielectric anisotropy, and contains a specific bicyclic compound having a large optical anisotropy and a small viscosity as a first component and a specific compound having a large maximum temperature and a large dielectric anisotropy as a second component, and may contain a specific compound having a small viscosity as a third component, a specific compound having a large dielectric anisotropy as a fourth component and a specific compound having a large dielectric anisotropy as a fifth component, and a liquid crystal display device includes the composition.

A gonadotropin-releasing hormone antagonistic composition, which comprises an optionally substituted condensed-bicyclic compound consisting of a homo or hetero 5 to 7 membered ring and a homo or hetero 5 to 7 membered ring is effective as a propylactic or therapeutic agent for the prevention or treatment of several hormone dependent diseases, for example, a sex hormone dependent cancer (e.g. prostatic cancer, cancer of uterine cervix, breast cancer, pituitary adenoma), benign prostatic hypertrophy, myoma of the uterus, endometriosis, precocious puberty, amenorrhea, premenstrual syndrome, polycystic ovary syndrome and acne vulgaris; is effective as a fertility controlling agent in both sexes (e.g. a pregnancy controlling agent and a menstrual cycle controlling agent); can be used as a contraceptive of male or female, as an ovulation-inducing agent of female; can be used as an infertility treating agent by using a rebound effect owing to a stoppage of administration thereof; is useful as modulating estrous cycles in animals in the field of animal husbandry, as an agent fro improving the quality of edible meat or promoting the growth of animals; is useful as an agent of spawning promotion in fish.

A liquid crystal composition and an AM liquid crystal display device are described. The liquid crystal composition has a negative dielectric anisotropy, contains a specific compound having a large negative dielectric anisotropy as a first component and a two-ring compound having a small viscosity as a second component, and may further contain a specific compound having a large negative dielectric anisotropy as a third component, a specific compound having a small viscosity as a fourth component and a specific compound having a large negative dielectric anisotropy as a fifth component. The AM liquid crystal display device includes the liquid crystal composition.

A porous solid acid catalyst having high concentration of acidic sites and a large surface area includes a porous silica support and a sulfonated carbon layer disposed within the pores of the silica support. The catalyst, in certain embodiments, has a concentration of —SO3H groups of at least about 0.5 mmol / g and a predominant pore size of at least about 300 Å. The catalyst is used to catalyze a variety of acid-catalyzed reactions, including but not limited to alkylation, acylation, etherification, olefin hydration and alcohol dehydration, dimerization of olefin and bicyclic compounds, esterification and transesterification. For example, the catalyst can be used to catalyze esterification of free fatty acids (FFAs) and, in certain embodiments, to catalyze transesterification of triglycerides in fats and oils. The catalyst is prepared by impregnating a silica support with a phenol-containing material, processing the material to form a polymer, carbonizing the polymer to form a carbon layer within the silica support, and sulfonating the resulting carbon layer to form sulfonated carbon.

The present invention provides a new cyclic compound having a CCR antagonist activity, especially a CCR5 antagonist activity, and the use thereof. The compound of the present invention is represented by the formula: wherein, R<1 >is a 5- to 6-membered ring group which may be substituted; X<1 >is a bond or the like; ring A is a 5- to 6-membered ring group which may be substituted; ring B is a 8- to 10-membered ring group which may be substituted; X<2 >is a bivalent group of 1 to 4 atoms; Z<1 >is a bivalent cyclic ring group or the like; Z<2 >is a bond or the like; and R<2 >is an amino group, a nitrogen-containing heterocyclic group which may be substituted or the like, or a salt thereof.

The present invention relates to bicyclic compounds according to formula I, pharmaceutical compositions containing such compounds and methods of using such compounds in the treatment of androgen receptor-associated conditions, such as age-related diseases, for example sarcopenia, wherein R1, R2, R5, X, Y and n are defined herein.

The present invention relates to bicyclic compounds useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.

An organic oxidation catalyst for alcohols which is environmentally less harmful and with which efficient oxidation can be conducted. The oxidation catalyst for alcohols is a 1-alkyl-2-azadamantan-N-oxyl which has a nitroxyl group incorporated in the adamantane skeleton and was synthesized from as a base material a bicyclic compound obtained by the Grob-type ring-opening reaction of 1,3-adamantanediol. Due to the nitroxyl group on the adamantane skeleton, the α-position hydrogen is stabilized based on Bredt's rule and the stability of the oxoammonium group generated by the oxidation thereof is ensured. Compared to TEMPO, which is a conventional oxidation catalyst, this catalyst is reduced in steric hindrance and is usable in a wide range of reaction fields. Because of this, not only a primary alcohol but a secondary alcohol having a sterically complicated structure, which has been difficult to oxidize with TEMPO, can be oxidized at a high efficiency.

A liquid crystal composition having a nematic phase that includes two components, wherein the first component is a specific compound having negatively large dielectric anisotropy, and the second component is a specific two-ring compound having especially small viscosity, and a liquid crystal display device including the composition.

The invention provides compounds of Formula I: wherein Azabicyclo is W is where the variables have the definitions discussed herein. These compounds may be in the form of pharmaceutical salts or compositions, may be in pure enantiomeric form or racemic mixtures, and are useful in pharmaceuticals to treat a disease or condition in which α7 is known to be involved.